ATE332710T1 - Wachstumsinhibitor gegen leukämische zellen, der antisense-oligonukleotidderivate gegen das wilms- tumorgen enthält - Google Patents
Wachstumsinhibitor gegen leukämische zellen, der antisense-oligonukleotidderivate gegen das wilms- tumorgen enthältInfo
- Publication number
- ATE332710T1 ATE332710T1 AT96914430T AT96914430T ATE332710T1 AT E332710 T1 ATE332710 T1 AT E332710T1 AT 96914430 T AT96914430 T AT 96914430T AT 96914430 T AT96914430 T AT 96914430T AT E332710 T1 ATE332710 T1 AT E332710T1
- Authority
- AT
- Austria
- Prior art keywords
- antisense oligonucleotide
- growth inhibitor
- cells containing
- oligonucleotide derivatives
- leukemic cells
- Prior art date
Links
- 108091034117 Oligonucleotide Proteins 0.000 title abstract 2
- 239000000074 antisense oligonucleotide Substances 0.000 title abstract 2
- 238000012230 antisense oligonucleotides Methods 0.000 title abstract 2
- 239000003966 growth inhibitor Substances 0.000 title abstract 2
- 208000008383 Wilms tumor Diseases 0.000 title 1
- 201000008026 nephroblastoma Diseases 0.000 title 1
- 108700025700 Wilms Tumor Genes Proteins 0.000 abstract 2
- 230000010261 cell growth Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/311—Phosphotriesters
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/312—Phosphonates
- C12N2310/3125—Methylphosphonates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/313—Phosphorodithioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/314—Phosphoramidates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Veterinary Medicine (AREA)
- Plant Pathology (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP15667295 | 1995-06-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE332710T1 true ATE332710T1 (de) | 2006-08-15 |
Family
ID=15632793
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT96914430T ATE332710T1 (de) | 1995-06-01 | 1996-05-24 | Wachstumsinhibitor gegen leukämische zellen, der antisense-oligonukleotidderivate gegen das wilms- tumorgen enthält |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US6034235A (de) |
| EP (1) | EP0841068B1 (de) |
| AT (1) | ATE332710T1 (de) |
| AU (1) | AU5779696A (de) |
| DE (1) | DE69636339T2 (de) |
| ES (1) | ES2268705T3 (de) |
| WO (1) | WO1996038176A1 (de) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5855911A (en) * | 1995-08-29 | 1999-01-05 | Board Of Regents, The University Of Texas System | Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides |
| US7309692B1 (en) * | 1996-07-08 | 2007-12-18 | Board Of Regents, The University Of Texas System | Inhibition of chronic myelogenous leukemic cell growth by liposomal-antisense oligodeoxy-nucleotides targeting to GRB2 or CRK1 |
| US6977244B2 (en) * | 1996-10-04 | 2005-12-20 | Board Of Regents, The University Of Texas Systems | Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides |
| JP4789095B2 (ja) * | 1997-07-16 | 2011-10-05 | 治夫 杉山 | ウイルムス腫瘍遺伝子（ｗｔ１）に対する発現阻害物質を含んで成る固形腫瘍治療剤 |
| US20030092656A1 (en) * | 1997-07-16 | 2003-05-15 | Haruo Sugiyama | Therapeutic agents for treatment of solid tumors comprising an expression-inhibiting sustance against Wilms' tumor gene (WT1) |
| US7704962B1 (en) | 1997-10-03 | 2010-04-27 | Board Of Regents, The University Of Texas System | Small oligonucleotides with anti-tumor activity |
| US7285288B1 (en) | 1997-10-03 | 2007-10-23 | Board Of Regents, The University Of Texas System | Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides |
| BRPI9912663B8 (pt) | 1998-07-31 | 2021-07-06 | Int Inst Cancer Immunology Inc | vacina contra cáncer e polipeptìdeo. |
| US7329410B1 (en) | 1998-09-30 | 2008-02-12 | Corixa Corporation | Compositions and method for WT1 specific immunotherapy |
| US7144581B2 (en) * | 2000-10-09 | 2006-12-05 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
| US20030039635A1 (en) * | 1998-09-30 | 2003-02-27 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
| US7901693B2 (en) | 1998-09-30 | 2011-03-08 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
| US20030235557A1 (en) * | 1998-09-30 | 2003-12-25 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
| US7063854B1 (en) * | 1998-09-30 | 2006-06-20 | Corixa Corporation | Composition and methods for WTI specific immunotherapy |
| US7115272B1 (en) | 1998-09-30 | 2006-10-03 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
| US20030215458A1 (en) * | 1998-09-30 | 2003-11-20 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
| US7655249B2 (en) * | 1998-09-30 | 2010-02-02 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
| WO2002006297A1 (en) * | 2000-07-19 | 2002-01-24 | Chugai Seiyaku Kabushiki Kaisha | Novel antisense oligonucleotide derivatives against wilms's tumor gene |
| EP1371664B1 (de) * | 2001-03-22 | 2008-01-09 | International Institute of Cancer Immunology, Inc. | Wti-modifiziertes peptid |
| US7553494B2 (en) | 2001-08-24 | 2009-06-30 | Corixa Corporation | WT1 fusion proteins |
| EP1460898A4 (de) * | 2002-01-03 | 2006-05-24 | Univ Texas | Wt1-antisense-oligos für die hemmung von brustkrebs |
| ATE466084T1 (de) * | 2002-06-12 | 2010-05-15 | Int Inst Cancer Immunology Inc | Hla-a24-restringiertes krebsantigenpeptid |
| US7132100B2 (en) | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
| US7425618B2 (en) | 2002-06-14 | 2008-09-16 | Medimmune, Inc. | Stabilized anti-respiratory syncytial virus (RSV) antibody formulations |
| US7342092B2 (en) * | 2002-09-12 | 2008-03-11 | International Institute Of Cancer Immunology, Inc. | Cancer antigen peptide formulations |
| US7563810B2 (en) | 2002-11-06 | 2009-07-21 | Celgene Corporation | Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases |
| US8034831B2 (en) | 2002-11-06 | 2011-10-11 | Celgene Corporation | Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies |
| JP4498274B2 (ja) * | 2003-01-15 | 2010-07-07 | 株式会社癌免疫研究所 | 二量体化ペプチド |
| WO2004091510A2 (en) | 2003-04-11 | 2004-10-28 | Medimmune, Inc. | Recombinant il-9 antibodies and uses thereof |
| CA2536238C (en) | 2003-08-18 | 2015-04-07 | Medimmune, Inc. | Humanization of antibodies |
| WO2005087260A1 (en) * | 2004-03-04 | 2005-09-22 | Corixa Corporation | Co-encapsulated wt1 polypeptide and immunostimulant microsphere formulations and methods thereof |
| JP4762133B2 (ja) * | 2004-03-29 | 2011-08-31 | 治夫 杉山 | Ｗｔ１遺伝子の発現を抑制するマイクロｒｎａおよびその利用 |
| WO2005092394A1 (ja) * | 2004-03-29 | 2005-10-06 | Haruo Sugiyama | WT1遺伝子の発現を抑制するsiRNAおよびその利用 |
| WO2005093076A1 (ja) * | 2004-03-29 | 2005-10-06 | Haruo Sugiyama | 細胞集団の中から肝細胞、内皮細胞、または造血細胞の前駆細胞を分離する方法 |
| JP4879884B2 (ja) | 2004-04-12 | 2012-02-22 | メディミューン，エルエルシー | 抗−ｉｌ−９抗体製剤及びその使用法 |
| CA2585717A1 (en) | 2004-10-27 | 2006-05-04 | Medimmune Inc. | Modulation of antibody specificity by tailoring the affinity to cognate antigens |
| FR2877350B1 (fr) * | 2004-11-03 | 2010-08-27 | Centre Nat Rech Scient | IDENTIFICATION ET UTILISATION DE miRNAs IMPLIQUES DANS LA DIFFERENCIATION DE CELLULES ISSUES D'UNE LEUCEMIE MYELOIDE |
| EP1869192B1 (de) | 2005-03-18 | 2016-01-20 | MedImmune, LLC | Rahmenmischung von antikörpern |
| AU2006261920A1 (en) | 2005-06-23 | 2007-01-04 | Medimmune, Llc | Antibody formulations having optimized aggregation and fragmentation profiles |
| KR20070101610A (ko) * | 2006-04-11 | 2007-10-17 | 주식회사 바이오인프라 | Ａｎｔ２ 유전자의 발현을 억제하는 작은 간섭 ｒｎａ를이용한 암 유전자 치료 및 항암제 내성 극복방법 |
| US8399426B2 (en) * | 2006-04-11 | 2013-03-19 | Bioinfra Inc. | Method for treating breast cancer using adenine nucleotide translocator 2 (ANT2) siRNA or ANT2 shRNA |
| JP5209625B2 (ja) | 2006-08-28 | 2013-06-12 | 協和発酵キリン株式会社 | アンタゴニストのヒトｌｉｇｈｔ特異的ヒトモノクローナル抗体 |
| BRPI0809674A2 (pt) | 2007-03-30 | 2014-10-07 | Medimmune Llc | Formulação aquosa estéril, estável, forma de dosagem unitária farmacêutica, recipiente selado, kit, método para prevenir, controlar, tratar ou melhorar uma doença ou distúrbio inflamatório, composição, processo para a preparação de uma composição, e, método para estabilizar um anticorpo 13h5 |
| RU2010121967A (ru) | 2007-10-31 | 2011-12-10 | Медиммун, Ллк (Us) | Белковые каркасные структуры |
| AR085091A1 (es) | 2011-01-26 | 2013-09-11 | Kolltan Pharmaceuticals Inc | Anticuerpos anti-kit y sus usos |
| EP3381943B1 (de) | 2012-07-25 | 2022-03-16 | Celldex Therapeutics, Inc. | Anti-kit-antikörper und verwendungen davon |
| WO2014059028A1 (en) | 2012-10-09 | 2014-04-17 | Igenica, Inc. | Anti-c16orf54 antibodies and methods of use thereof |
| WO2014197849A2 (en) | 2013-06-06 | 2014-12-11 | Igenica Biotherapeutics, Inc. | Anti-c10orf54 antibodies and uses thereof |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| DK3229838T3 (da) | 2014-12-11 | 2020-10-19 | Pf Medicament | Anti-C10orf54-antistoffer og anvendelser deraf |
| FI3265123T3 (fi) | 2015-03-03 | 2023-01-31 | Vasta-aineita, käyttöjä & menetelmiä | |
| WO2017096051A1 (en) | 2015-12-02 | 2017-06-08 | Stcube & Co., Inc. | Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof |
| EP3383908A1 (de) | 2015-12-02 | 2018-10-10 | Stsciences, Inc. | Spezifische antikörper gegen glykosylierten btla (b- und t-lymphozyt-attenuator) |
| EP3534947A1 (de) | 2016-11-03 | 2019-09-11 | Kymab Limited | Antikörper, kombinationen mit antikörpern, biomarker, verwendungen und verfahren |
| WO2018222685A1 (en) | 2017-05-31 | 2018-12-06 | Stcube & Co., Inc. | Methods of treating cancer using antibodies and molecules that immunospecifically bind to btn1a1 |
| CA3065301A1 (en) | 2017-05-31 | 2018-12-06 | Stcube & Co., Inc. | Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof |
| WO2018226671A1 (en) | 2017-06-06 | 2018-12-13 | Stcube & Co., Inc. | Methods of treating cancer using antibodies and molecules that bind to btn1a1 or btn1a1-ligands |
| IL280199B2 (en) | 2018-07-20 | 2025-08-01 | Pf Medicament | Receptor for vista |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1992013091A1 (en) * | 1991-01-18 | 1992-08-06 | Oncogene Science, Inc. | Methods of transcriptionally modulating expression of oncogenes and tumor suppressor genes |
| US5622835A (en) * | 1994-04-28 | 1997-04-22 | The Wistar Institute Of Anatomy & Biology | WT1 monoclonal antibodies |
-
1996
- 1996-05-24 AT AT96914430T patent/ATE332710T1/de not_active IP Right Cessation
- 1996-05-24 AU AU57796/96A patent/AU5779696A/en not_active Abandoned
- 1996-05-24 ES ES96914430T patent/ES2268705T3/es not_active Expired - Lifetime
- 1996-05-24 EP EP96914430A patent/EP0841068B1/de not_active Expired - Lifetime
- 1996-05-24 DE DE69636339T patent/DE69636339T2/de not_active Expired - Lifetime
- 1996-05-24 WO PCT/JP1996/001394 patent/WO1996038176A1/ja not_active Ceased
- 1996-05-24 US US08/952,664 patent/US6034235A/en not_active Expired - Lifetime
-
2000
- 2000-01-20 US US09/487,874 patent/US6277832B1/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| EP0841068B1 (de) | 2006-07-12 |
| DE69636339T2 (de) | 2007-07-19 |
| DE69636339D1 (de) | 2006-08-24 |
| US6277832B1 (en) | 2001-08-21 |
| EP0841068A4 (de) | 2004-07-07 |
| EP0841068A1 (de) | 1998-05-13 |
| US6034235A (en) | 2000-03-07 |
| ES2268705T3 (es) | 2007-03-16 |
| AU5779696A (en) | 1996-12-18 |
| WO1996038176A1 (fr) | 1996-12-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE332710T1 (de) | Wachstumsinhibitor gegen leukämische zellen, der antisense-oligonukleotidderivate gegen das wilms- tumorgen enthält | |
| FI931109L (fi) | Peptider och nukleinsyrasekvenser, som haenfoer sig till epstein-barr-virus | |
| NO912473D0 (no) | Tynn, roerformet, selvbaerende elektrode for elektrokjemiske celler. | |
| KR20010014183A (ko) | 술폰아미드 화합물 및 그의 의약 용도 | |
| MY120235A (en) | Aryloxyarylsulfonylamino hydroxamic acid derivatives | |
| AU6787496A (en) | Use of phenol substituted diphosphonates as antineoplastic agents | |
| IT1264901B1 (it) | Analoghi eterociclici di 1,2,4-triazolo(15-c)pirimidine ad attivita' antagonista per il recettore a2 dell'adenosina | |
| DE69012601D1 (de) | Gentherapie durch stützgewebebezügliche Zellen. | |
| ATE320491T1 (de) | Optimierung von zellen für die endogene genaktivierung | |
| IT1284656B1 (it) | Cella elettrolitica | |
| DE69941869D1 (de) | Spezifische gene der basalen endosperm transferzellschicht (betl) | |
| NO20000097L (no) | Isolerte dendrittcellemembranproteingener | |
| NO994431L (no) | Ny formulering | |
| DK1135513T3 (da) | Adenovirus-medieret genterapi | |
| TR199802648A3 (tr) | Gen tedavisi için nüklein asit yapilari. | |
| DE59607589D1 (de) | N-aryl-1,2,4-triazolin-5-one | |
| AU8243198A (en) | Remedies for solid tumor containing wilms' tumor gene (wt1) expression inhibitors | |
| AR026925A1 (es) | Nuevos derivados de azabiciclooctano utiles en el tratamiento de arritmias cardiacas | |
| AUPO684997A0 (en) | Polyphenol oxidase genes from banana, tobacco & pineapple | |
| TR199802511T2 (xx) | S�bstit�e edilmi� pirazolil-pirazol t�revleri | |
| AU6960396A (en) | Batten disease gene | |
| NO305440B1 (no) | Gestagent aktive 19,11-broede 4-°strener | |
| AU7057398A (en) | Chromosome transfer (xmmct) to es cells, induced during the exposure of microcells to radiation | |
| AU2206401A (en) | Labelled ascorbic acid derivatives | |
| AU5920799A (en) | Genes from human chromosome 11p15.5 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |